المؤلفون: Malahleha, Mookho, Laher, Fatima, Dilraj, Athmanundh, Smith, Philip, Gray, Glenda E., Grove, Doug, Odhiambo, Jackline A., Andrasik, Michele P., Grunenberg, Nicole A., Moodie, Zoe, Huang, Yunda, Borate, Bhavesh R., Gillespie, Kevin M., Allen, Mary, Atujuna, Millicent, Singh, Nishanta, Kalonji, Dishiki, Meintjes, Graeme, Kotze, Phillip, Bekker, Linda-Gail, Janes, Holly

المساهمون: GlaxoSmithKline, National Institute of Health, National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, South African Medical Research Council, Triclinium Clinical Development, Sanofi Pasteur

المصدر: AIDS and Behavior ; volume 27, issue 9, page 3027-3037 ; ISSN 1090-7165 1573-3254

مصطلحات موضوعية: Infectious Diseases, Public Health, Environmental and Occupational Health, Social Psychology

الوصف: In South Africa, HIV acquisition risk has been studied less in people assigned male at birth. We studied the associations between risk behaviors, clinical features and HIV incidence amongst males in two South African HIV preventive vaccine efficacy trials. We used Cox proportional hazards models to test for associations between demographics, sexual behaviors, clinical variables and HIV acquisition among males followed in the HVTN 503 (n = 219) and HVTN 702 (n = 1611) trials. Most males reported no male sexual partners (99.09% in HVTN 503) or identified as heterosexual (88.08% in HVTN 702). Annual HIV incidence was 1.39% in HVTN 503 (95% CI 0.76–2.32%) and 1.33% in HVTN 702 (95% CI 0.80–2.07%). Increased HIV acquisition was significantly associated with anal sex (HR 6.32, 95% CI 3.44–11.62), transactional sex (HR 3.42, 95% CI 1.80–6.50), and non-heterosexual identity (HR 16.23, 95%CI 8.13–32.41) in univariate analyses and non-heterosexual identity (HR 14.99, 95% CI 4.99–45.04; p < 0.01) in multivariate analysis. It is appropriate that prevention efforts in South Africa, although focused on the severe epidemic in young women, also encompass key male populations, including men who have sex with men, but also men who engage in anal or transactional sex.

الإتاحة: https://doi.org/10.1007/s10461-023-04025-zTest

المؤلفون: Mashingaidze, Rujeko, Moodie, Zoe, Allen, Mary, Bekker, Linda-Gail, Grove, Doug, Grunenberg, Nicole, Huang, Yunda, Janes, Holly E., Lazarus, Erica Maxine, Malahleha, Mookho, Nchabeleng, Maphoshane, Laher, Fatima

المساهمون: Yi, Siyan

المصدر: PLOS Global Public Health ; volume 3, issue 4, page e0001782 ; ISSN 2767-3375

الوصف: There is limited data about bacterial STIs in MSM populations in sub-Saharan Africa. Our retrospective analysis used data from the HVTN 702 HIV vaccine clinical trial (October 2016 to July 2021). We evaluated multiple variables. Polymerase chain reaction testing was conducted on urine and rectal samples to detect Neisseria gonorrhoea (NG) and Chlamydia trachomatis (CT) every 6 months. Syphilis serology was conducted at month 0 and thereafter every 12 months. We calculated STI prevalence and the associated 95% confidence intervals until 24 months of follow-up. The trial enrolled 183 participants who identified as male or transgender female, and of homosexual or bisexual orientation. Of these, 173 had STI testing done at month 0, median age was 23 (IQR 20–25) years, with median 20.5 (IQR 17.5–24.8) months follow-up (FU). The clinical trial also enrolled and performed month 0 STI testing on 3389 female participants, median age 23 (IQR 21–27) years, median 24.8 (IQR 18.8–24.8) months FU and 1080 non-MSM males with a median age of 27 (IQR 24–31) years, median 24.8 (IQR 23–24.8) months FU. At month 0, CT prevalence was similar in MSM and females (26.0% vs 23.0%, p = 0.492) but was more prevalent in MSM compared to non-MSM males (26.0% vs 14.3%, p = 0.001). CT was the most prevalent STI among MSM at months 0 and 6 but declined from month 0 to month 6 (26.0% vs 17.1%, p = 0.023). In contrast, NG did not decline in MSM between months 0 and 6 (8.1% vs 7.1%, p = 0.680) nor did syphilis prevalence between months 0 and 12 (5.2% vs 3.8%, p = 0.588). Bacterial STI burden is higher in MSM compared to non-MSM males, and CT is the most prevalent bacterial STI amongst MSM. Preventive STI vaccines, especially against CT, may be helpful to develop.

الإتاحة: https://doi.org/10.1371/journal.pgph.0001782Test

المؤلفون: Moodie, Zoe, Dintwe, One, Sawant, Sheetal, Grove, Doug, Huang, Yunda, Janes, Holly, Heptinstall, Jack, Omar, Faatima Laher, Cohen, Kristen, De Rosa, Stephen C, Zhang, Lu, Yates, Nicole L, Sarzotti-Kelsoe, Marcella, Seaton, Kelly E, Laher, Fatima, Bekker, Linda Gail, Malahleha, Mookho, Innes, Craig, Kassim, Sheetal, Naicker, Nivashnee, Govender, Vaneshree, Sebe, Modulakgotla, Singh, Nishanta, Kotze, Philip, Lazarus, Erica, Nchabeleng, Maphoshane, Ward, Amy M, Brumskine, William, Dubula, Thozama, Randhawa, April K, Grunenberg, Nicole, Hural, John, Kee, Jia Jin, Benkeser, David, Jin, Yutong, Carpp, Lindsay N, Allen, Mary, D'Souza, Patricia, Tartaglia, James, DiazGranados, Carlos A, Koutsoukos, Marguerite, Gilbert, Peter B, Kublin, James G, Corey, Lawrence, Andersen-Nissen, Erica, Gray, Glenda E, Tomaras, Georgia D, McElrath, M Juliana

المصدر: The Journal of Infectious Diseases 226(2) 246-257

الوصف: This is the accepted manuscript version of the work published in its final form as Moodie, Z., Dintwe, O., Sawant, S., Grove, D., Huang, Y., Janes, H., Heptinstall, J., Omar, F. L., Cohen, K., Stephen C De Rosa., Zhang, L., Yates, N. L., Sarzotti-Kelsoe, M., Seaton, K. E., Laher, F., Bekker, L. G., Malahleha, M., Innes, C., Kassim, S., . McElrath, M. J. (2022). Analysis of the HIV Vaccine Trials Network 702 Phase 2b3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. The Journal of Infectious Diseases, 226(2), 246-257. https://doi.org/10.1093/infdis/jiac260Test Deposited by shareyourpaper.org and openaccessbutton.org. We've taken reasonable steps to ensure this content doesn't violate copyright. However, if you think it does you can request a takedown by emailing help@openaccessbutton.org.

العلاقة: https://zenodo.org/communities/gates-foundationTest; https://zenodo.org/record/7071884Test; https://doi.org/10.5281/zenodo.7071884Test; oai:zenodo.org:7071884

الإتاحة: https://doi.org/10.5281/zenodo.7071884Test
https://doi.org/10.1093/infdis/jiac260Test
https://doi.org/10.5281/zenodo.7071883Test
https://zenodo.org/record/7071884Test

المؤلفون: Brouillette, Liane, Grove, Doug, Hinga, Briana

الوصف: This study looks at the impact of a cost-effective professional development model in which teaching artists helped early elementary teachers master arts-based strategies for boosting the oral language development of English language learners (ELLs). Teaching artists visited K-2 classrooms for 50 minutes weekly for 28 weeks. Student scores on the listening and speaking sections of the California English Language Development Test (CELDT) were used to determine the impact on language development. The experimental group consisted of 267 students; the comparison group consisted of 2981 students. The analysis of the CELDT listening and speaking scores, fall 2010 to fall 2011, showed significantly more improvement for students in the experimental group. This research has implications for school leaders who, in times of tight budgets, seek professional development opportunities that can assist teachers in addressing the language development needs of ELLs.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/4xv3f63hTest

المؤلفون: Lemos, Maria P., Lazarus, Erica, Isaacs, Abby, Dietrich, Janan, Morgan, Cecilia, Huang, Yunda, Grove, Doug, Andrasik, Michele, Laher, Fatima, Hural, John, Chung, Eva, Dragavon, Joan, Puren, Adrian, Gulati, Reena K., Coombs, Robert, McElrath, Margaret Juliana, Gray, Glenda, Kublin, James G.

المصدر: JAIDS Journal of Acquired Immune Deficiency Syndromes ; volume 81, issue 2, page e39-e48 ; ISSN 1525-4135

الوصف: Background: Measurements of HIV exposure could help identify subpopulations at highest risk of acquisition and improve the design of HIV prevention efficacy trials and public health interventions. The HVTN 915 study evaluated the feasibility of self-administered vaginal swabs for detection of HIV virions to assess exposure. Methods: Fifty 18- to 25-year-old sexually active HIV-seronegative women using contraception were enrolled in Soweto, South Africa. Participants self-administered daily vaginal swabs and answered sexual behavior questions through mobile phone for 90 days. Clinician-administered vaginal swabs, behavioral questionnaires, HIV diagnostic testing, and counseling were performed at 8 clinic visits. Glycogen concentrations assessed adherence to swabbing. Y-chromosome DNA (Yc-DNA) assessed the accuracy of reported condom use. HIV exposure was measured by virion polymerase chain reaction in swabs from 41 women who reported unprotected vaginal sex during follow-up. Results: Glycogen was detected in 315/336 (93.8%) participant-collected and in all clinician-collected swabs. Approximately 20/39 daily swabs (51.3%) linked to mobile reports of unprotected sex tested positive for Yc-DNA, whereas 10/187 swabs collected after 3 days of abstinence or protected sex (5.3%) had detectable Yc-DNA. No participant became HIV infected during the study; yet, exposure to HIV was detected by nucleic acids in 2 vaginal swabs from 1 participant, collected less than 1 hour after coitus. Conclusion: There was high adherence to daily vaginal swabbing. Daily mobile surveys had accurate reporting of unprotected sex. Detection of HIV in self-collected vaginal swabs from an uninfected participant demonstrated it was possible to measure HIV exposure, but the detection rate was lower than expected.

الإتاحة: https://doi.org/10.1097/qai.0000000000002015Test
https://journals.lww.com/00126334-201906010-00013Test

المؤلفون: Williams, Wilton B., Liao, Hua-Xin, Moody, M. Anthony, Kepler, Thomas B., Alam, S. Munir, Gao, Feng, Wiehe, Kevin, Trama, Ashley M., Jones, Kathryn, Zhang, Ruijun, Song, Hongshuo, Marshall, Dawn J., Whitesides, John F., Sawatzki, Kaitlin, Hua, Axin, Liu, Pinghuang, Tay, Matthew Z., Seaton, Kelly E., Shen, Xiaoying, Foulger, Andrew, Lloyd, Krissey E., Parks, Robert, Pollara, Justin, Ferrari, Guido, Yu, Jae-Sung, Vandergrift, Nathan, Montefiori, David C., Sobieszczyk, Magdalena E., Hammer, Scott, Karuna, Shelly, Gilbert, Peter, Grove, Doug, Grunenberg, Nicole, McElrath, M. Juliana, Mascola, John R., Koup, Richard A., Corey, Lawrence, Nabel, Gary J., Morgan, Cecilia, Churchyard, Gavin, Maenza, Janine, Keefer, Michael, Graham, Barney S., Baden, Lindsey R., Tomaras, Georgia D., Haynes, Barton F.

المصدر: Science, 2015 Aug . 349(6249), 705-705.

الوصول الحر: http://www.jstor.org/stable/24748896Test

المؤلفون: Corrigan, Michael W., Grove, Doug, Vincent, Philip F.

المصدر: Corwin. 2011.

تمت مراجعته من قبل الزملاء: N

Page Count: 320

الواصفات: Teacher Effectiveness, Academic Achievement, Educational Change, Educational Improvement, Decision Making, Data, Instructional Improvement, Holistic Approach, Educational Assessment, Teacher Persistence

مستخلص: Schools aren't one dimensional. Your decision making shouldn't be either. If you want to look beyond student test scores to identify the specific areas that need improvement in your school, you will find practical tools for assessing multiple areas with confidence here. The authors detail a step-by-step framework for identifying, collecting, analyzing, and using data as a basis for driving school improvement in the right direction. Based on more than 40 years of research, this seven-dimensional model will help enhance your school's curriculum, community, climate, and character by applying data to these key processes: (1) Assessing student achievement; (2) Modifying instruction based on data findings; (3) Improving school performance; and (4) Retaining effective teachers. The result is a holistic and accurate instrument for making the changes needed to improve student learning. Included are assessment tools, process charts, graphic organizers, rubrics, tables, numerous examples, and background research. An index is included.

Abstractor: As Provided

الوصول الحر: http://www.corwin.com/books/Book235604?subject=C00&status=New&pager.offset=20Test

المؤلفون: Gray, Glenda E., Bekker, Linda‑Gail, Laher, Fatima, Malahleha, Mookho, Allen, Mary, Moodie, Zoe, Grunenberg, Nicole, Huang, Yunda, Grove, Doug, Prigmore, Brittany, Kee, Jia J., Benkeser, David, Hural, John, Innes, Craig, Lazarus, Erica, Meintjes, Graeme, Naicker, Nivashnee, Kalonji, Dishiki, Nchabeleng, Maphoshane, Sebe, Modulakgotla, Singh, Nishanta, Kotze, Philip, Kassim, Sheetal, Dubula, Thozama, Naicker, Vimla, Brumskine, William, Ncayiya, Cleon N., Ward, Amy M., Garrett, Nigel, Kistnasami, Girisha, Gaffoor, Zakir, Selepe, Pearl, Makhoba, Philisiwe B., Mathebula, Matsontso P., Mda, Pamela, Adonis, Tania, Mapetla, Katlego S., Modibedi, Bontle, Philip, Tricia, Kobane, Gladys, Bentley, Carter, Ramirez, Shelly, Takuva, Simbarashe G., Jones, Megan, Sikhosana, Mpho, Atujuna, Millicent, Andrasik, Michele, Hejazi, Nima S., Puren, Adrian, Wiesner, Lubbe, Phogat, Sanjay, Granados, Carlos Diaz, Koutsoukos, Marguerite, Van Der Meeren, Olivier, Barnett, Susan W., Kanesa‑Thasan, Niranjan, Kublin, James G., McElrath, Juliana, Gilbert, Peter B., Janes, Holly, Corey, Lawrence

مصطلحات موضوعية: Infection, Immunogenicity, Vaccine, Human immunodeficiency virus type 1 (HIV-1)

الوصف: BACKGROUND : A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1–2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa. METHODS : In this phase 2b–3 trial, we randomly assigned 5404 adults without HIV-1 infection to receive the vaccine (2704 participants) or placebo (2700 participants). The vaccine regimen consisted of injections of ALVAC-HIV at months 0 and 1, followed by four booster injections of ALVAC-HIV plus bivalent subtype C gp120–MF59 adjuvant at months 3, 6, 12, and 18. The primary efficacy outcome was the occurrence of HIV-1 infection from randomization to 24 months. RESULTS : In January 2020, prespecified criteria for non-efficacy were met at an interim analysis; further vaccinations were subsequently halted. The median age of the trial participants was 24 years; 70% of the participants were women. The incidence of adverse events was similar in the vaccine and placebo groups. During the 24-month followup, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P = 0.84). CONCLUSIONS : The ALVAC–gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. ; Supported by grants (HHSN272201300033C and HHSN272201600012C) to Novartis Vaccines and Diagnostics (now part of the GlaxoSmithKline [GSK] Biologicals) by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for the selection and process development of the two gp120 envelope proteins TV1.C and 1086.C; by the Bill and Melinda Gates Foundation Global Health Grant ...

العلاقة: https://repository.up.ac.za/handle/2263/88063Test; Gray, G.E., Bekker, L.-G., Laher, F. et al. 2021, 'Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults', New England Journal of Medicine, vol. 384, no. 12, pp. 1089-1100, doi : 10.1056/NEJMoa2031499.; 0028-4793 (print); 1533-4406 (online)

الإتاحة: https://doi.org/10.1056/NEJMoa2031499Test
https://repository.up.ac.za/handle/2263/88063Test

المؤلفون: Churchyard, Gavin J, Morgan, Cecilia, Adams, Elizabeth, Hural, John, Graham, Barney S, Moodie, Zoe, Grove, Doug, Gray, Glenda, Bekker, Linda-Gail, McElrath, M Juliana

المصدر: PLoS One ; http://journals.plos.org/plosoneTest

مصطلحات موضوعية: T cells, Vaccines, Cytotoxic T cells, Enzyme-linked immunoassays, Antibodies, Antibody response, Cytokines, HIV-1

الوصف: BACKGROUND: The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB, envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5) HIV-1 with matching inserts was evaluated in HIV-seronegative participants from South Africa, United States, Latin America and the Caribbean. METHODS: 480 participants were evenly randomized to receive either: DNA (4 mg IM by Biojector) at 0, 1 and 2 months, followed by rAd5 (10 10 PU IM by needle/syringe) at 6 months; or placebo. Participants were monitored for reactogenicity and adverse events throughout the 12-month study. Peak and duration of HIV-specific humoral and cellular immune responses were evaluated after the prime and boost. RESULTS: The vaccine was well tolerated and safe. T-cell responses, detected by interferon-γ (IFN-γ) ELISpot to global potential T-cell epitopes (PTEs) were observed in 70.8% (136/192) of vaccine recipients overall, most frequently to Gag (54.7%) and to Env (54.2%). In U.S. vaccine recipients T-cell responses were less frequent in Ad5 sero-positive versus sero-negative vaccine recipients (62.5% versus 85.7% respectively, p = 0.035). The frequency of HIV-specific CD4+ and CD8+ T-cell responses detected by intracellular cytokine staining were similar (41.8% and 47.2% respectively) and most secreted ≥2 cytokines. The vaccine induced a high frequency (83.7%-94.6%) of binding antibody responses to consensus Group M, and Clades A, B and C gp140 Env oligomers. Antibody responses to Gag were elicited in 46% of vaccine recipients. CONCLUSION: The vaccine regimen was well-tolerated and induced polyfunctional CD4+ and CD8+ T-cells and multi-clade anti-Env binding antibodies. Trial Registration: ClinicalTrials.gov NCT00125970

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/11427/15280Test; http://dx.doi.org/10.1371/journal.pone.0021225Test; https://open.uct.ac.za/bitstream/11427/15280/1/Churchyard_phase_IIA_randomized_clinical_trial_2011.pdfTest

الإتاحة: https://doi.org/10.1371/journal.pone.0021225Test
http://hdl.handle.net/11427/15280Test
https://open.uct.ac.za/bitstream/11427/15280/1/Churchyard_phase_IIA_randomized_clinical_trial_2011.pdfTest

المؤلفون: Andrasik, Michele, Grove, Doug, Broder, Gail, Scott, Hyman, Allen, Mary, Karuna, Shelly

المساهمون: NIAID

المصدر: Vaccine ; volume 37, issue 29, page 3911-3917 ; ISSN 0264-410X

مصطلحات موضوعية: Infectious Diseases, Public Health, Environmental and Occupational Health, General Veterinary, General Immunology and Microbiology, Molecular Medicine

الإتاحة: https://doi.org/10.1016/j.vaccine.2019.05.016Test
https://api.elsevier.com/content/article/PII:S0264410X19306309?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0264410X19306309?httpAccept=text/plainTest